Waldencast (WALD) to Release Quarterly Earnings on Tuesday

Waldencast (NASDAQ:WALD) is anticipated to post its results before the market opens on Tuesday, September 30th. Analysts expect Waldencast to post earnings of ($0.0750) per share and revenue of $67.66 million for the quarter.

Waldencast Stock Down 0.5%

Shares of WALD opened at $2.01 on Friday. The firm has a fifty day simple moving average of $1.86 and a two-hundred day simple moving average of $2.36. The company has a current ratio of 1.35, a quick ratio of 0.66 and a debt-to-equity ratio of 0.21. Waldencast has a 1-year low of $1.48 and a 1-year high of $4.18.

Wall Street Analysts Forecast Growth

Separately, Telsey Advisory Group reduced their price objective on Waldencast from $4.00 to $3.00 and set an “outperform” rating for the company in a research report on Wednesday, August 20th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.97.

Institutional Trading of Waldencast

Hedge funds have recently bought and sold shares of the stock. Invesco Ltd. purchased a new stake in Waldencast in the second quarter worth about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Waldencast by 57.9% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,130 shares of the company’s stock worth $57,000 after acquiring an additional 8,485 shares in the last quarter. Jane Street Group LLC bought a new stake in Waldencast during the 1st quarter worth approximately $77,000. Rhumbline Advisers raised its stake in Waldencast by 15.2% during the 1st quarter. Rhumbline Advisers now owns 61,630 shares of the company’s stock worth $185,000 after acquiring an additional 8,151 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Waldencast by 62.2% during the second quarter. Geode Capital Management LLC now owns 586,566 shares of the company’s stock valued at $1,437,000 after purchasing an additional 224,905 shares in the last quarter. Institutional investors own 41.97% of the company’s stock.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.